Professional
Added to YB: 2024-08-01
Pitch date: 2024-06-30
UCB.BR [bullish]
UCB SA
+70.9%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Market Cap
EUR 29.9B
Pitch Price
EUR 137.68
Price Target
N/A
Dividend
0.86%
EV/EBITDA
27.40
P/E
128.82
EV/Sales
5.95
Sector
Pharmaceuticals
Category
growth
Show full summary:
Artisan Global Equity Fund Added On: UCB SA
UCB.BR: Increased position as Bimzelx® psoriasis drug rollout succeeds, potential $5B peak sales. Evenity® (osteoporosis) & Fintepla® (epilepsy) gaining global approvals. Strong upside potential in demographics/health care theme.
Read full article (1 min)